Charles River Laboratories International

The drug research and development process is highly complex, lengthy and expensive, yet essential for delivering safe and effective therapies to patients. To help our clients navigate this process, Charles River offers a wide range of products and services that span the entire drug discovery and development continuum and can be tailored to specific research conditions.

Company Growth (employees)
Wilmington, US
Size (employees)
11,000 (est)+28%
Charles River Laboratories International was founded in 1947 and is headquartered in Wilmington, US

Charles River Laboratories International Office Locations

Charles River Laboratories International has an office in Wilmington
Wilmington, US (HQ)
251 Ballardvale Street

Charles River Laboratories International Metrics

Charles River Laboratories International Financial Metrics

Revenue (2016)

$1.7 b

Revenue growth (2015-16), %


Gross profit

$1.4 b

Gross profit margin (2016), %


Net income (2016)

$156.4 m

Market capitalization (21-Mar-2017)

$4.2 b

Closing share price (21-Mar-2017)


Cash (31-Dec-2016)

$117.6 m
Charles River Laboratories International's current market capitalization is $4.2 b.
Charles River Laboratories International's revenue was reported to be $1.7 b in FY, 2016 which is a 23.3% increase from the previous period.
FY, 2013FY, 2014FY, 2015FY, 2016


$1.2 b$1.3 b$1.4 b$1.7 b

Revenue growth, %


Cost of goods sold

$264 m$277 m

Gross profit

$671.4 m$739.1 m$1.1 b$1.4 b

Gross profit Margin, %



$151.4 m$177.7 m$206.4 m$237.4 m

EBIT margin, %


Interest income

$1 m$1.3 m

Net Income

$104.2 m$128.4 m$151.1 m$156.4 m
FY, 2013FY, 2014FY, 2015FY, 2016


$155.9 m$160 m$117.9 m$117.6 m

Accounts Receivable

$220.6 m$258 m$270.1 m$364.1 m


$89.4 m$89 m$93.7 m$95.8 m

Current Assets

$552.6 m$606.9 m$559.2 m$656.8 m


$676.2 m$676.8 m$678 m$755.8 m


$230.7 m$321.1 m$438.8 m$787.5 m

Total Assets

$1.6 b$1.9 b$2.1 b$2.7 b

Accounts Payable

$31.8 m$33.8 m$36.7 m$68.5 m

Current Liabilities

$247 m$296.2 m$311.8 m$429.6 m

Additional Paid-in Capital

$2.2 b$2.3 b$2.4 b$2.5 b

Retained Earnings

($265.5 m)($138.8 m)$10.5 m$165.3 m

Total Equity

$664.7 m$737.6 m$839.1 m

Financial Leverage

2.5 x2.8 x3.2 x
FY, 2013FY, 2014FY, 2015FY, 2016

Net Income

$104.2 m$128.2 m$151.1 m$156.4 m

Depreciation and Amortization

$96.6 m$96.4 m$24.2 m$41.7 m

Accounts Receivable

($17 m)($53 m)


($1.6 m)($3 m)$3.4 m($4 m)

Accounts Payable

($7.1 m)$4.6 m$1.2 m$22.1 m

Cash From Operating Activities

$209 m$252.1 m$288.2 m$300.4 m

Capital Expenditures

$39.2 m($56.9 m)($63.3 m)($55.3 m)

Cash From Investing Activities

($74 m)($298 m)($320.3 m)($686.4 m)

Interest Paid

$12 m$10.2 m$11.1 m$22.8 m

Income Taxes Paid

$19.1 m$29.7 m$24.4 m$42.9 m

Free Cash Flow

$169.9 m$309.1 m$351.5 m$355.7 m

Charles River Laboratories International Market Value History

Charles River Laboratories International Online Presence

Charles River Laboratories International News

Charles River Laboratories International Company Life

You may also be interested in